home / stock / mnpr / mnpr message board
Subject | By | Source | When |
---|---|---|---|
$1.40 Not nice. | willlbone | investorshub | 03/28/2023 3:52:30 PM |
$4+ nice | wesley_ | investorshub | 11/08/2022 9:35:40 PM |
Monopar Announces Completion of Phase 2b Enrollment and | subslover | investorshub | 10/05/2022 1:28:03 PM |
Well not looking great at present. However | Condors rugby | investorshub | 02/23/2021 2:47:53 PM |
With a price target of 49 and extremely | Condors rugby | investorshub | 02/12/2021 4:46:27 PM |
but f---ing low flot dont you think | all right all right | investorshub | 02/11/2021 4:28:40 PM |
Very active trading on low float. Looks | Condors rugby | investorshub | 02/11/2021 3:10:57 PM |
taking a position at 13.86 low float. lets go | makingitnow | investorshub | 01/28/2021 1:26:58 PM |
Monopar Therapeutics shares are trading higher after Roth | crudeoil24 | investorshub | 01/28/2021 12:51:16 PM |
Monopar Therapeutics Inc. is a clinical stage biopharmaceutical | crudeoil24 | investorshub | 01/28/2021 12:50:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Monopar Therapeutics Inc. Company Name:
MNPR Stock Symbol:
NASDAQ Market:
Monopar Therapeutics Inc. Website:
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceuti...
Highlights: Builds on Companies’ respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs WILMETTE, ...
WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead...